CONNECT WITH US
HealthTech

HealthTech

Abbott gets FDA nod for updates to heart failure monitoring system

MedTech Dive logo

Published on

Add as a preferred source on Google
Abbott gets FDA nod for updates to heart failure monitoring system

Patients can view their pulmonary artery pressure readings on their phone with the CardioMEMS updates, giving them a more active role in their care.

Abbott said the updates will help patients stay informed and connected between doctor visits. CardioMEMS was developed to detect the signs of worsening heart failure before symptoms appear. As heart failure gets worse, pressure in the artery between the heart and the lungs can rise.

"Heart failure can worsen before patients notice shortness of breath, swelling or weight gain,” said Dr. Andrew Sauer, a cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, in a statement from Abbott. “Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop.”

In addition to letting patients view their readings, the CardioMEMS updates include a software feature that allows clinicians to adjust medications based on changes in pulmonary artery pressure. The feature, called dynamic treatment plan, can send instructions directly to patients through an app.

Abbott said it expects to make dynamic treatment plans and the CardioGuide HF App available later this year.

Earlier this year, Abbott received an FDA nod for a version of CardioMEMS with a much smaller reader. CardioMEMS received a national coverage determination from the Centers for Medicare and Medicaid Services in 2025.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.